| Literature DB >> 30325614 |
Lianchao Jin1,2, Mingshuai Wang1, Feiya Yang1, Yinong Niu1, Nianzeng Xing1.
Abstract
PURPOSE: To describe our technique and outcomes for laparoscopic intracorporeal ileal neobladder (ICNB) reconstruction.Entities:
Keywords: Cystectomy ; Laparoscopy; Quality of Life
Mesh:
Year: 2018 PMID: 30325614 PMCID: PMC6442179 DOI: 10.1590/S1677-5538.IBJU.2017.0505
Source DB: PubMed Journal: Int Braz J Urol ISSN: 1677-5538 Impact factor: 1.541
Figure 1Trocar placement and patient position.
Figure 2A) Interrupted suturing of the posterior wall of the reservoir using 2-0 Vicryl suture. B) Pulling the interrupted knots to tension ileum to facilitate suturing (“pulling technique”). C) Closure of the distal half of the anterior wall of the reservoir. D) The proximal half of the back wall of the reservoir was anastomosed with the urethra back wall. E) The catheter and two single J stents were introduced through urethra. F) The ureters were spatulated for 2-3 cm and were end-to-end anastomosed with ipsilateral limb in a continuous manner, using 3-0 vicryl sutures, respectively.
Patient's Characteristics.
| VARIABLES | RESULTS | |
|---|---|---|
| Patients, n | 21 | |
| Age (mean±SD), year | 60±10.1 | |
| Male, n (%) | 19 (90.5%) | |
| BMI (mean ± SD), kg/m2 | 24.5±3.9 | |
| Neoadjuvant chemotherapy, n (%) | 4 (19.0%) | |
| Charlson comorbidity index (median [range]) | 4 (2-6) | |
|
| ||
| 1-2 | 21 | |
| 3-4 | 0 | |
| Smoking history, n (%) | 9 (42.9%) | |
| Abdominal surgery history, n (%) | 5 (23.8%) | |
BMI = body mass index; ASA = American Society of Anesthesiologists
Surgical Outcomes.
| VARIABLES | RESULTS | |
|---|---|---|
| Total operative time (mean±SD), min | 345±66.9 | |
| Time of LRC and PLND / (mean±SD), min | 106±22.0 | |
| Time of ICNB (mean±SD), min | 204±46.4 | |
| EBL (mean±SD), mL | 192±146 | |
| Transfusion, n (%) | 0 | |
| ICU after surgery, n (%) | 0 | |
| POD 1 VAS score (median [range]) | 1 (0-4) | |
| Time of intake of liquid diet / (median [range]), day | 4 (3-12) | |
| Time of ambulation (median [range]), day | 1 (1-4) | |
| Length of hospital stay / (median [range]), day | 14 (8-22) | |
|
| ||
| Minor (I-II) | 4 (19.0%) | |
| Major (III-V) | 0 | |
|
| ||
| Minor (I-II) | 3 (14.3%) | |
| Major (III-V) | 1 (4.8%) | |
| 30-day readmission, n (%) | 1 (4.8%) | |
| Lymph node yield (mean±SD), n | 18±9.2 | |
| Positive surgical margin, n (%) | 0 | |
| Incidental prostate adenocarcinoma, n (%) | 2 (10.5%) | |
| Lymph node positive patients, n (%) | 3 (14.3%) | |
LRC=laparoscopic radical cystectomy; PLND=pelvic lymph node dissection; ICNB=intracorporeal neobladder; EBL=estimated blood loss; POD=postoperative; VAS=Visual analogue scale
Figure 3Learning Curve of the laparoscopic radical cystectomy with intracorporeal orthotopic neobladder.
Comparison of the first and last ten cases.
| Case (1-10) | Case (12-21) | P | |
|---|---|---|---|
| Total operative time (mean±SD), min | 393±47.6 | 297±50.0 | <0.001 |
| LRC and PLND time (mean±SD), min | 114±25.9 | 97.7±15.8 | 0.11 |
| ICNB time (mean±SD), min | 237±33.7 | 169±31.3 | <0.001 |
| EBL (mean±SD), mL | 155±95.6 | 240±182.3 | 0.21 |
LRC=laparoscopic radical cystectomy; PLND=pelvic lymph node dissection; ICNB=intracorporeal neobladder; EBL=estimated blood loss
Continence and Neobladder function Outcomes.
| VARIABLES | 6 MONTHS | 12 MONTHS | |
|---|---|---|---|
|
| |||
| Day time continence 0-1 pad/d | 15/17 (88.2%) | 12/14 (85.7%) | |
| Night time continence 0-1 pad/d | 6/14 (42.9%) | 8/14 (57.1%) | |
|
| |||
| Neobladder Capacity (Median [range]), mL | 214 (170-330) | 375 (310-495) | |
| Residual volume (Median [range]), mL | 27 (0-135) | 38 (20-160) | |
| Max flow rate (Median [range]), mL/sec | 17 (9-22) | 19 (8-21) | |
| Clean intermittent catheterization | 0 | 1 | |
Figure 4A) EORTC QLQ-C30 Functional Scale: a high scale score represents a high/healthy level of functioning (0-100). For the global quality of life scale, a high scale score represents a low level of functioning. B) EORTC QLQ-C30 Symptoms scale and single items: a high scale score represents a high level of symptomatology/problems (0-100). C) EORTC QLQ-BLM30: a high scale score represents a high level of symptomatology/problems (0-100).